Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
80
DOCS Quote, Financials, Valuation and Earnings
Last price:
$58.23
Seasonality move
:
-0.88%
Day range:
$56.25 - $59.14
52-week range:
$22.96 - $61.75
Dividend yield:
0%
P/E ratio:
66.87x
P/S ratio:
22.55x
P/B ratio:
11.30x
Volume:
2.9M
Avg. volume:
2.5M
1-year change:
108.38%
Market cap:
$10.9B
Revenue:
$475.4M
EPS (TTM):
$0.87
Analysts' Opinion
-
Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 13 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $55.24, Doximity has an estimated downside of -5.06% from its current price of $58.18.
-
Price Target UpsideAccording to analysts, the highest upside price target is $70.00 representing -100% upside increase from its current price of $58.18.
Fair Value
-
According to the consensus of 17 analysts, Doximity has -5.06% downside to fair value with a price target of $55.24 per share.
DOCS vs. S&P 500
-
Over the past 5 trading days, Doximity has overperformed the S&P 500 by 7.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Doximity does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Doximity has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Doximity reported revenues of $136.8M.
Earnings Growth
-
Doximity has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Doximity reported earnings per share of $0.22.
Enterprise value:
10.1B
EV / Invested capital:
10.46x
Price / LTM sales:
22.55x
EV / EBIT:
49.81x
EV / Revenue:
19.46x
PEG ratio (5yr expected):
1.34x
EV / Free cash flow:
46.26x
Price / Operating cash flow:
53.61x
Enterprise value / EBITDA:
47.40x
Gross Profit (TTM):
$464.9M
Return On Assets:
16.43%
Net Income Margin (TTM):
33.69%
Return On Equity:
19.29%
Return On Invested Capital:
19.29%
Operating Margin:
40.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $384.4M | $448.3M | $516.8M | $113.6M | $136.8M | |
| Gross Profit | $335.2M | $395.2M | $464.9M | $100.9M | $123.2M | |
| Operating Income | $117.5M | $142.7M | $201.9M | $41.7M | $55.4M | |
| EBITDA | $125.2M | $153.3M | $212.1M | $44.3M | $58.1M | |
| Diluted EPS | $0.65 | $0.58 | $0.87 | $0.15 | $0.22 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $829.6M | $847.9M | $862.8M | $957.7M | |
| Total Assets | -- | $869.3M | $1B | $1B | $1.1B | |
| Current Liabilities | -- | $95.6M | $118.1M | $123.2M | $132.3M | |
| Total Liabilities | -- | $96.7M | $149.4M | $154.1M | $157.3M | |
| Total Equity | -- | $772.6M | $879M | $871.5M | $961.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $158.5M | $165.4M | $223.6M | $12.9M | $68.3M | |
| Cash From Investing | -$109.2M | $67.3M | $18.1M | -$50.1M | $24.2M | |
| Cash From Financing | -$55.2M | -$198M | -$165.8M | -$161.1M | -$19.7M | |
| Free Cash Flow | $150.8M | $160.3M | $217.4M | $11.6M | $66.8M | |
DOCS
Sector
Market Cap
$10.9B
$45.6M
Price % of 52-Week High
94.22%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
2.07%
-0.74%
1-Year Price Total Return
108.38%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$54.28
200-day SMA
Buy
Level
$35.18
Bollinger Bands (100)
Buy
Level
35.56 - 51.38
Chaikin Money Flow
Buy
Level
42.5M
20-day SMA
Buy
Level
$53.74
Relative Strength Index (RSI14)
Buy
Level
67.26
ADX Line
Buy
Level
19.93
Williams %R
Sell
Level
-11.7349
50-day SMA
Buy
Level
$49.21
MACD (12, 26)
Buy
Level
1.75
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
28.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (18.8456)
Buy
CA Score
(Annual)
Level (1.975)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-4.8322)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Stock Forecast FAQ
In the current month, DOCS has received 4 Buy ratings 13 Hold ratings, and 0 Sell ratings. The DOCS average analyst price target in the past 3 months is $55.24.
-
Where Will Doximity Stock Be In 1 Year?
According to analysts, the consensus estimate is that Doximity share price will drop to $55.24 per share over the next 12 months.
-
What Do Analysts Say About Doximity?
Analysts are divided on their view about Doximity share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Doximity is a Sell and believe this share price will rise from its current level to $31.00.
-
What Is Doximity's Price Target?
The price target for Doximity over the next 1-year time period is forecast to be $55.24 according to 17 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 13 analysts rate the stock a Hold.
-
Is DOCS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Doximity is a Hold. 13 of 17 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DOCS?
You can purchase shares of Doximity via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Doximity shares.
-
What Is The Doximity Share Price Today?
Doximity was last trading at $58.23 per share. This represents the most recent stock quote for Doximity. Yesterday, Doximity closed at $58.18 per share.
-
How To Buy Doximity Stock Online?
In order to purchase Doximity stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
